What is Diagnostics Direct?
Diagnostics Direct is a seasoned provider of state-of-the-art CLIA Waived Sexually Transmitted Disease (STD) diagnostic tests. The company distinguishes itself through its offerings that are characterized by ease of administration, simplicity in reading results, and high accuracy. These attributes are crucial for enabling faster diagnoses and facilitating immediate patient treatment, a critical factor in managing public health.
How much funding has Diagnostics Direct raised?
Diagnostics Direct has raised a total of $65K across 1 funding round:
Debt
$65K
Debt (2021): $65K with participation from PPP
Key Investors in Diagnostics Direct
PPP
Public-Private Partnership
What's next for Diagnostics Direct?
With significant Series B/C stage funding, Diagnostics Direct is poised for a period of accelerated growth and market penetration. The recent influx of substantial expansion capital suggests a strategic focus on scaling operations, enhancing product development, and potentially broadening its market reach. This investment will likely enable the company to solidify its position as a leader in the diagnostic testing sector, particularly in the critical area of STD detection.
See full Diagnostics Direct company page
